Research Papers:

Differential regulation of mTOR signaling determines sensitivity to AKT inhibition in diffuse large B cell lymphoma

Scott A. Ezell, Suping Wang, Teeru Bihani, Zhongwu Lai, Shaun E. Grosskurth, Suprawee Tepsuporn, Barry R. Davies, Dennis Huszar and Kate F. Byth _

PDF  |  HTML  |  Supplementary Files  |  How to cite

Oncotarget. 2016; 7:9163-9174. https://doi.org/10.18632/oncotarget.7036

Metrics: PDF 1867 views  |   HTML 2294 views  |   ?  


Scott A. Ezell1, Suping Wang1, Teeru Bihani1, Zhongwu Lai1, Shaun E. Grosskurth1, Suprawee Tepsuporn1, Barry R. Davies2, Dennis Huszar1 and Kate F. Byth1

1 AstraZeneca Oncology, Waltham, Massachusetts, MA, USA

2 AstraZeneca Oncology, Macclesfield, Cheshire, UK

Correspondence to:

Kate F. Byth, email:

Keywords: mTOR, DLBCL, AKT, Ibrutinib, S6K1

Received: July 15, 2015 Accepted: January 19, 2016 Published: January 27, 2016


Agents that target components of the PI3K/AKT/mTOR pathway are under investigation for the treatment of diffuse large B cell lymphoma (DLBCL). Given the highly heterogeneous nature of DLBCL, it is not clear whether all subtypes of DLBCL will be susceptible to PI3K pathway inhibition, or which kinase within this pathway is the most favorable target. Pharmacological profiling of a panel of DLBCL cell lines revealed a subset of DLBCL that was resistant to AKT inhibition. Strikingly, sensitivity to AKT inhibitors correlated with the ability of these inhibitors to block phosphorylation of S6K1 and ribosomal protein S6. Cell lines resistant to AKT inhibition activated S6K1 independent of AKT either through upregulation of PIM2 or through activation by B cell receptor (BCR) signaling components. Finally, combined inhibition of AKT and BTK, PIM2, or S6K1 proved to be an effective strategy to overcome resistance to AKT inhibition in DLBCL.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 7036